Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
XBiotech
Biotech
J&J ends work on eczema drug, a $610M dent to ex-XBiotech asset
Johnson & Johnson will stop work in atopic dermatitis but continue in another skin disease with an ex-XBiotech monoclonal antibody it paid $750M for.
Kyle LaHucik
Feb 2, 2022 5:42pm
XBiotech's worst fears come true as EMA rejects lead drug
May 19, 2017 9:35am
XBiotech slumps on likely EMA rejection of cancer drug
Apr 21, 2017 7:19am
Dodgy data analysis sees XBiotech shares plummet
Jul 6, 2016 6:40am
